Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01292187Phase 2Completed

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

Role: lead

NCT00803686Phase 2Completed

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

Role: lead

NCT00959764Phase 3Completed

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

Role: lead

NCT00620854Phase 2Completed

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

Role: lead

All 4 trials loaded